@morellifit full peptide stack: AM repair + Epitalon/Pinealon + DSIP + Tirz microdose + exercise mimetics
People ask me what peptides I take every day, so let me share my full (current) peptide stack, broken down by what it does and when I take it. > AM peptides - BPC-157: 2mg - GHK-Cu: 2mg - TB-500: 2mg I take these three together every morning for tissue repair and skin (5 days on, 2 days off) > PM peptides: sleep + longevity (20-day cycle) - Epitalon: 5mg - Pinealon: 1mg I take them a couple of hours before bed. My RHR has dropped 8-10 bpm into the high 40s. I'm sleeping less and feeling better. > DSIP (as needed, 1-2x/week) I usually take 250-300mcg before bed. It hits deep sleep hard. I ran it 5-7 days straight once and woke up groggy, so now I pulse it. It's powerful, but you have to monitor it. > Metabolic stack (current cycle) - Tirzepatide: 0.75mg, 2-3x per week - 5-amino-1MQ: 150mg/day (finishing a 6-week run) - SLU-PP-332: 1mg/day (tapering off) - MOTS-c: 5mg, 3x/week, 30 min pre-workout (just layering in) The way I run this is that GLP does the heavy lifting on fat loss, but the other compounds (like SLU-PP-332) shine when you're cycling off. I layer them, i.e., as one finishes, the next comes on. They overlap, but I don't run them all in tandem for the full cycle. > Off-cycle rotation When I'm off the GLP, I rotate tesofensine with SLU-PP-332. One or the other, not both. (Though I'm planning to stack them on my next off-cycle to see what happens.) > Topical - GHK-Cu cream: once nightly - Blueprint peptide hair serum + my own GHK-Cu powder mixed in This is n=1, and not medical advice. But this is what's actually in my protocol right now.
The best-disclosed stack on the site so far. Morelli has doses, timing, cycling logic, and explicit n=1 learning ('ran DSIP daily, got groggy, now I pulse it'). He treats Tirzepatide as a fat-loss backbone and layers SLU-PP-332, 5-amino-1MQ, and MOTS-c with intentional sequencing. Three concerns. The Tirzepatide microdose (1.5-2.25mg/wk total) is below the trial starting dose. SLU-PP-332 and 5-amino-1MQ are preclinical-only with essentially zero human data. And 2mg/day TB-500 is daily continuous use of a compound typically loaded weekly.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 80 | B- | 25% | Epitalon + Pinealon 20-day cycle is more aligned with the published Khavinson protocols than continuous use, though 5mg/day × 20 days is still high cumulative. GHK-Cu adds aging-relevant collagen mechanisms. |
| Cognition | — | Not targeted | — | No ingredient with a primary cognitive mechanism. |
| Sleep & recovery | 84 | B | 25% | Strong recovery axis: BPC-157 + TB-500 + GHK-Cu for tissue repair, Epitalon/Pinealon for sleep, DSIP pulsed thoughtfully for deep sleep. The DSIP n=1 learning ('ran it daily, got groggy') is the best example of dose-discipline in the corpus. |
| Energy & metabolism | 85 | B | 20% | Tirzepatide + MOTS-c covers metabolic basics; 5-amino-1MQ and SLU-PP-332 add (very) experimental exercise-mimetic mechanisms on top. |
| Body recomposition | 87 | B+ | 30% | Tirzepatide as a fat-loss foundation with sophisticated layering of mimetics on top is the most thoughtful recomp pharmacology in the corpus. Held off the A range by the microdose Tirz question and the experimental status of SLU-PP-332 and 5-amino-1MQ. |
Ingredients (12)
BPC-157
- Dose
- 2mg/day, 5 days on, 2 days off · AM
- Mechanism
- Pentadecapeptide derived from a gastric protein; preclinical evidence for angiogenesis, fibroblast migration, and growth factor signaling. No published human RCTs.
- Take
- 2mg/day is well above typical research-vendor protocols (200-500mcg/day). 5/2 cycling reduces cumulative exposure but the dose is still high. Author's tissue-repair framing makes sense for an active fitness influencer; the cycling pattern is at least thoughtful.
GHK-Cu
- Dose
- 2mg AM (injectable) + nightly topical cream + powder mixed into hair serum · AM injectable, PM topical, ongoing scalp
- Mechanism
- Tripeptide-copper complex with well-studied effects on collagen and elastin synthesis when applied topically. Injectable use less characterized.
- Take
- Multi-route GHK-Cu use is unusual but reasonable: topical and injectable target different things. The injectable 2mg AM is on the high end of typical 1-3mg subQ. The topical cream is the route with the strongest evidence base (cosmetic/dermal collagen synthesis). Mixing GHK-Cu powder into Bryan Johnson's Blueprint hair serum is enterprising but not necessarily additive over what the commercial serum already contains.
TB-500
- Dose
- 2mg/day, 5 days on, 2 days off · AM
- Mechanism
- Synthetic fragment of thymosin beta-4; preclinical evidence for actin-binding effects on cell motility and tissue repair. No human trials in this indication.
- Take
- 2mg/day daily is daily continuous use of a compound typically loaded at 2-5mg/week then maintained. Cumulative weekly exposure (10mg/week with 5/2 cycling) is 2-5x typical enthusiast use. Author's tissue-repair framing is the standard rationale; the dose is on the aggressive side.
Epitalon
- Dose
- 5mg/day, 20-day cycle · PM, a couple of hours before bed
- Mechanism
- Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a pineal extract. Claimed to upregulate telomerase, restore melatonin secretion, and normalize circadian rhythms in older adults.
- Take
- 5mg/day for a 20-day cycle is closer to the published Khavinson protocol pattern than the continuous daily use we've seen elsewhere on the site, though still high cumulative (100mg total per cycle). Author claims RHR dropped 8-10 bpm; that's a meaningful subjective signal but RHR drops at that magnitude usually reflect overall fitness/training rather than peptide effects.
Pinealon
- Dose
- 1mg/day, 20-day cycle · PM, a couple of hours before bed
- Mechanism
- Synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator class. Claimed neuroprotective and cognitive effects via gene-expression modulation. Human evidence is essentially limited to the Khavinson group's publications.
- Take
- Khavinson-class pineal-derived tripeptide with even thinner evidence base than Epitalon. 1mg/day for 20 days is in the typical enthusiast range. Often paired with Epitalon for stacked pineal-axis modulation, which is what's happening here.
DSIP
- Dose
- 250-300mcg, 1-2x/week · before bed, pulsed
- Mechanism
- Nonapeptide first isolated from rabbit brain in the 1970s; proposed to modulate non-REM sleep depth and stress response, possibly via opioid-system and HPA-axis interactions. Mechanism is incompletely characterized.
- Take
- Dose is in standard range. The n=1 framing here is the best in the corpus: 'ran it daily, woke up groggy, now I pulse it.' That's actual learning applied to dose-frequency, which is exactly what self-experimenters should be doing. The pulsing approach also matches DSIP's mechanism (acute deep-sleep effects rather than sustained receptor occupancy).
Tirzepatide
Tirzepatide on peptidelist.org ↗
- Dose
- 0.75mg, 2-3x/week (~1.5-2.25mg/wk total) · split dosing across the week
- Mechanism
- Dual GLP-1 / GIP receptor agonist. Phase 3 SURMOUNT-1 trial showed ~22% bodyweight loss at 72 weeks at the 15mg dose. FDA-approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes.
- Take
- Microdose split-dosing is unusual. Standard Zepbound titration starts at 2.5mg/week as a single weekly injection. 0.75mg × 2-3x/week totals 1.5-2.25mg/week, below the trial starting dose. The split-dose approach may aim for smoother PK (Tirz half-life is ~5 days, so weekly is already smooth), or may reflect dose-finding for low-side-effect maintenance. Author doesn't specify whether it's Zepbound or compounded, but at this dose and split frequency, compounded tirzepatide is the more practical sourcing.
5-amino-1MQ
- Dose
- 150mg/day (finishing 6-week run) · daily, 6-week cycle
- Mechanism
- NNMT (nicotinamide N-methyltransferase) inhibitor. NNMT consumes nicotinamide and methyl donors; inhibition is proposed to increase NAD+ availability and reduce adipocyte expansion. Preclinical metabolic effects in mouse models; no published human trials.
- Take
- 5-amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor with preclinical evidence for metabolic effects in obese mice. Human data is essentially zero; available through research-chemical vendors only. 150mg/day is the typical enthusiast dose, but 'typical' here means 'what people on Reddit say,' not 'evidence-supported.' Author treating it as cycle-on/cycle-off is the right discipline given the unknown long-term safety.
SLU-PP-332
- Dose
- 1mg/day (tapering off) · daily, tapering
- Mechanism
- Pan-ERR (estrogen-related receptor) α/β/γ agonist. Preclinical mouse data shows increased fatty acid oxidation, exercise capacity, and improved insulin sensitivity. Marketed in enthusiast circles as an 'exercise mimetic.' No published human trials.
- Take
- SLU-PP-332 is a research-stage ERRα/β/γ agonist developed at Saint Louis University, marketed in enthusiast circles as an 'exercise mimetic' based on preclinical mouse data showing increased oxidative capacity and fat oxidation. Human data is essentially zero. 1mg/day is the typical research-vendor protocol; the compound is sold as a powder and reconstituted. Author tapering off is good discipline.
MOTS-c
- Dose
- 5mg, 3x/week, 30 min pre-workout · pre-workout, 3x/week
- Mechanism
- Mitochondrial-derived 16-amino-acid peptide encoded by mitochondrial DNA. AMPK activator with metabolic effects on insulin sensitivity, glucose homeostasis, and exercise capacity in animal and small human studies.
- Take
- 5mg 3x/week (15mg/week) is at the upper end of typical research-vendor protocols (5-10mg/week). Pre-workout timing aligns with MOTS-c's AMPK-activating mechanism, which is most relevant during exercise. Real and interesting mitochondrial biology; the dose is aggressive but defensible.
Tesofensine
- Dose
- off-cycle rotation with SLU-PP-332 (specific dose unspecified) · off-GLP cycles
- Mechanism
- Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin). Originally developed for Parkinson's; weight-loss effects are downstream of catecholamine elevation. Phase 3 trial data showed ~10% bodyweight loss at 1mg/day vs ~2% placebo.
- Take
- Tesofensine is a triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) with real weight-loss data from Phase 3 trials. Approved in Mexico under brand Nupeida; not FDA-approved in the US. Author uses it as an off-GLP rotation, alternating with SLU-PP-332. Dose isn't specified, which matters: typical Phase 3 doses were 0.25-1mg/day with meaningful blood pressure and heart rate effects. Sourcing is either Mexican pharmacy or gray-market research vendor.
Blueprint peptide hair serum
- Dose
- topical, mixed with extra GHK-Cu powder · nightly application
- Mechanism
- Commercial peptide-based topical scalp serum from Bryan Johnson's Blueprint brand. Composition focuses on peptides (GHK-Cu and others) and supporting actives targeting follicular function, hair-shaft thickness, and scalp inflammation.
- Take
- Blueprint's peptide hair serum is a commercial product from Bryan Johnson's Blueprint brand. The specific ingredient list shifts; common inclusions are GHK-Cu, biotin, and other peptide/keratin support actives. Author mixes in additional GHK-Cu powder, which is a vendor-modification approach. Topical scalp peptides have modest evidence for hair density/diameter outcomes in some user populations.
Risks & interactions
- Microdose Tirzepatide is below trial efficacy thresholdmedium
0.75mg × 2-3x/week totals 1.5-2.25mg/week. Phase 3 SURMOUNT-1 used 5-15mg/week, with the 2.5mg starting dose primarily for titration tolerance rather than efficacy. At Morelli's microdose, the metabolic effects are likely meaningful but well below trial-tested benefit. Whatever Morelli is getting from his stack, the Tirz contribution is smaller than the dose framing suggests, and other compounds (5-amino-1MQ, MOTS-c, SLU-PP-332) may be doing more of the work than acknowledged.
- SLU-PP-332 and 5-amino-1MQ have essentially zero human datamedium
Both are preclinical-only research compounds. SLU-PP-332 has one published mouse study showing exercise-mimetic effects; 5-amino-1MQ has preclinical metabolic-mouse data. Neither has human safety, dosing, or efficacy data. Author's cycling discipline reduces but doesn't eliminate the long-term-unknown-risk profile. These are the most speculative compounds in the stack.
- 2mg/day TB-500 is daily continuous use of a compound typically loaded weeklymedium
Standard enthusiast TB-500 protocols dose 2-5mg per week (loading) or weekly maintenance. 2mg/day with 5/2 cycling totals 10mg/week of weekly cumulative exposure, 2-5x typical use. TB-500's mechanism (actin-binding cell motility) doesn't have a clear dose-response ceiling in published work, but high cumulative use over months is unstudied territory.
- Tesofensine sourcing concernsmedium
Not FDA-approved in the US. Sourcing is either Mexican pharmacy (legitimate, requires international acquisition) or gray-market research vendor (sourcing concerns apply). Author doesn't specify, and the dose isn't disclosed; both matter because tesofensine has meaningful blood-pressure and heart-rate effects.
- Twelve concurrent compounds defeat n=1 attributionlow
Even with intentional cycling and layering, twelve compounds across categories means subjective changes (the claimed RHR drop, 'sleeping less and feeling better') can't be cleanly attributed. Author's cycling strategy reduces but doesn't eliminate this. The 8-10 bpm RHR drop especially is the kind of change usually driven by overall training and recovery, not peptide additions.
- Mixing extra GHK-Cu into commercial hair serum is unmeasuredlow
The Blueprint hair serum already includes GHK-Cu among its actives. Adding additional powder may push concentration above what the formulation was designed to support; topical scalp peptides have a sweet spot, not a 'more is better' curve. Probably benign but unmeasured.
Morelli already does this well for DSIP ('ran it daily, got groggy, now I pulse it'). The same discipline applied to the experimental compounds would turn the cycling strategy into something approximating real signal. SLU-PP-332 and 5-amino-1MQ have essentially no human data; a structured n=1 with body comp + RHR trends + sleep tracker data before and after a discrete cycle is the most valuable contribution someone with Morelli's audience can make. The current 'these shine when you cycle off' framing is plausible but unmeasured.
Estimated cost
Twelve compounds across categories. AM peptides (BPC + TB-500 + GHK-Cu at 2mg/day each) run ~$200-400/mo at research-vendor pricing. PM peptides (Epitalon + Pinealon, 20-day cycles) ~$60-120/mo amortized. DSIP ~$30-50/mo. Tirzepatide compounded ~$100-200/mo at this microdose; Zepbound LillyDirect $299/mo. 5-amino-1MQ ~$60-120/mo, SLU-PP-332 ~$80-150/mo. MOTS-c ~$60-100/mo. Tesofensine (off-cycle) variable depending on sourcing. Topicals ~$50-100/mo.